Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGENT: D-Cycloserine Augmentation of iTBS in Depression
NCT05591677Phase 2Active, not recruiting
- Sponsor
- Alfred Health
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of d-cycloserine in major depressive disorder (MDD), sponsored by Alfred Health. Started Apr 2023; status: active, not recruiting.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05591677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05591677.